Last Updated : May 18, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort ascending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Sensipar | Cinacalcet hydrochloride | Secondary hyper-parathyroidism in chronic kidney disease | Do not list | Complete | ||
| Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Active | |||
| Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Omnaris | Ciclesonide nasal spray | Allergic Rhinitis (seasonal and perennial) | Do not list | Complete | ||
| Alvesco | Ciclesonide | asthma | List | Complete | ||
| Ledaga | chlormethine hydrochloride | T-cell lymphoma | Do not reimburse | Complete | ||
| Erbitux | Cetuximab | Cancelled | ||||
| Erbitux | Cetuximab | Metastatic Colorectal Cancer | Do not reimburse | Complete | ||
| Cimzia | certolizumab pegol | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
| Cimzia | Certolizumab pegol | Ankylosing spondylitis | List with criteria/condition | Complete |
Last Updated : May 18, 2024